Myriad Genetics (NASDAQ:MYGN) executives highlighted fourth quarter and full-year 2025 results alongside a slate of planned ...

Scientists have identified how specific genetic changes function in cells to influence disease risk and other human health traits. By probing regions of DNA previously linked to disease, the work has ...

Myriad Genetics delivered a solid Q4 2025 earnings beat, with positive adjusted EPS and strong test volume growth. Click for ...

Opus Genetics targets inherited retinal diseases with one-dose AAV gene augmentations. Read why IRD stock is a Buy.

Myriad Genetics (MYGN) surged 24% in premarket trading on Tuesday after reporting a quarterly earnings beat and outlining a 2026 revenue target of $860 million to $880 million while highlighting ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported in Q4 CY2025, but sales were flat year on year at $209.8 ...

Genetics is the study of genes and how they influence characteristics and health. Through a variety of technological methods, environmental factors, and lifestyle choices, it is possible to alter some ...

UD developmental biologist studies genetics of jaw joint disorder with NIH funding ...

At Mass General Brigham, Boston researchers pair gene studies with a 12-point Brain Care Score to help lower the risk of Alzheimer's and other brain disorders.

For a long time, we’ve been sold the idea that Genghis Khan, the 13th-century founder of the Mongol Empire, was so phenomenally prolific that one in 200 men alive today carries his exact Y chromosome.

Such an expanded partnership builds upon the firms’ successful partnership in representing many raspberry varieties emanating from The James Hutton Institute ...